Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARRIS - Another partner -- Ignore unavailable to you. Want to Upgrade?

To: chirodoc who wrote (235)	11/20/1997 5:42:00 PM
From: Pseudo Biologist	Read Replies (2) \| Respond to of 353

chirodoc, here is a short version of my reply to your questions on the Xoma thread. First, I am still digesting the ARRS/SQNA merger. I've owned these two in the past but have been out for a while. Arris has reinvented itself a few times, first with the Kephri acquisition to become a "protease inhibitor house" and now with Sequana to become ?? I used to like the old old guard of Michael Ross et al, but these guys have been gone since shortly after Kephri. Not sure what to make of the current people, although I know many think highly of Mr. Walker (hope I got the name right). On Incyte, I am not sure if I can add much to what Rocketman has posted in the past. This was a "re-invention" that did work (boy, what an understatement) as the company went from a more or less classical so-so biotech to a very successful, to date, genomics/software hybrid. This appears to have been done at the right time and with exceptional execution. On MLNM, I like their science and overall business plan but have not spent a lot of time examining their management and/or decision making. PB P.S. MLNM thanked to the 12-15 range after the ChemGenics acquisition; maybe you'll get lucky and Axys (?) will recover, just as MLNM did, after the dust settles.